Video Series

The SPOTLIGHT study results presented at the 2023 ASCO GI Cancers Symposium are explored by Dr Marshall.

Dr Michos offers strategies to successfully reduce LDL levels in patients with cardiovascular disease.

GA treatment options in various steps in FDA approval process are discussed by a panel of medical experts.

Maria Lopes, MD, MS, highlights the utilization of health care resources to optimize GA treatment impact.

Dr Marshall shares insights directed at the use of real-world evidence [RWE] and its impact on unmet needs in colorectal cancer [CRC] treatment.

Erin Michos, MD, MHS, opens a discussion surrounding the utilization of bempedoic acid for patients with intolerance to statin-based therapies.

Dr Haumschild leads a discussion surrounding comorbidities associated with geographic atrophy.

David Lally, MD, highlights risk factors associated with geographic atrophy.

In their closing thoughts, the expert panelists discuss the future of the disease state and treatment options, and how they expect provider, patient, and payer value perception to change in the future.

Panelists provide their closing thoughts on the disease state and treatment landscape of multidrug-resistant HIV.

Dr Lopes and Mr Driffin discuss cost considerations and utilization barriers inhibiting treatment for patients with multidrug-resistant HIV.

Maria Lopes, MD, MS, and Mr Driffin explore total cost of care affected by various multidrug-resistant treatment regimens.

A medical expert discusses real-world analyses surrounding the use of ctDNA.

Geographic atrophy disease progression is explored by a panel of medical experts.

Ryan Haumschild, PharmD, MS, MBA, opens a discussion surrounding the disease landscape of geographic atrophy.

Dr Sheth discusses the evolution of access to treatment for AMD/DME over the past few years and initiatives to expand treatment access.

Joseph Coney, MD, FASRS, FACS, discusses switching anti-VEGF agents in the treatment of wet AMD and what payers should consider when switching anti-VEGF therapies.

Daniel Driffin, BS, MPH, provides insights regarding factors influencing patient adherence to multidrug-resistant HIV treatment.

Dr Sension underlines the value of CD4 recovery from payer and clinician perspectives.

The effect of ctDNA in the GI cancer treatment landscape are illustrated by Dr Marshall.

Veeral Sheth, MD, MBA, FACS, Joseph Coney, MD, FASRS, FACS, and Caesar Luo, MD, FASRS, FACS discuss their experience with utilization management strategies.

Caesar Luo, MD, FASRS, FACS discusses the biggest barriers for patients with wet AMD and DME to receiving optimal treatment and his strategies to overcome these barriers.

Key opinion leaders highlight barriers to MDR HIV treatment adherence.

The panel discusses considerations for payers as well as patient adherence to treatment in MDR HIV.

John L. Marshall, MD, provides insight into the SUNLIGHT study findings presented during the 2023 ASCO Gastrointestinal Cancers Symposium.

In their final thoughts, Drs Brinton, Baum and Michos provide insights on the trajectory of treatment in HoFH.

Medical experts discuss the unmet needs surrounding homozygous FH.

A panel of medical experts discuss diagnostic imaging surrounding DME and wet AMD.